Konstantina G. Yiannopoulou

TL;DR: Current symptomatic treatments and new potential disease-modifying therapies for AD that are currently being studied in phase I–III trials are discussed.

TL;DR: A review of disease-modifying therapies for Alzheimer disease can be found in this paper, where the authors discuss potential disease modifying therapies that are currently being studied and potential individualized therapeutic frameworks that can be proved beneficial for patients with AD.

TL;DR: Diagnostic and statistical advances, which have been recently integrated in clinical trials, are relevant to the recent failures of studies of disease-modifying treatments for AD.

TL;DR: The novel coronavirus disease (COVID‐19) was first detected in Mainland China in December 2019, and soon it spread throughout the world, with multiple physical and psychological consequences across the affected populations.

TL;DR: Clinical and laboratory data extracted from published cases of SLE‐associated ATM, fulfilling the Transverse Myelitis Consortium Working Group diagnostic criteria, provided information on aPL, and detection of circulating aPL at ATM onset appears unreliable to suggest a thrombotic cause and perhaps not enough to dictate therapeutic anticoagulation.